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Brief CommunicationExercise increases circulating GDF15 in humansMaximilian Kleinert 1,2, Christoffer Clemmensen 3, Kim A. Sjøberg 1, Christian Strini Carl 1,
Jacob Fuglsbjerg Jeppesen 4, Jørgen F.P. Wojtaszewski 1, Bente Kiens 1, Erik A. Richter 1,*ABSTRACT
Objective: The growth differentiation factor 15 (GDF15) is a stress-sensitive circulating factor that regulates systemic energy balance. Since
exercise is a transient physiological stress that has pleiotropic effects on whole-body energy metabolism, we herein explored the effect of
exercise on a) circulating GDF15 levels and b) GDF15 release from skeletal muscle in humans.
Methods: Seven healthy males either rested or exercised at 67% of their VO2max for 1 h and blood was sampled from the femoral artery and
femoral vein before, during, and after exercise. Plasma GDF15 concentrations were determined in these samples.
Results: Plasma GDF15 levels increased 34% with exercise (p < 0.001) and further increased to 64% above resting values at 120 min
(p < 0.001) after the cessation of exercise. There was no difference between the arterial and venous GDF15 concentration before, during, and
after exercise. During a resting control trial, GDF15 levels measured in the same subjects were unaltered.
Conclusions: Vigorous submaximal exercise increases circulating GDF15 levels in humans, but skeletal muscle tissue does not appear to be the
source.
 2018 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Obesity and associated health complications afﬂict millions of people
worldwide. Growth differentiation factor 15 (GDF15) has emerged as a
potential anti-obesity agent. It circulates as a 25-kDa homodimer and
is a member of the transforming growth factor- b (TGF-b) super family.
Originally identiﬁed in 1997 as a factor that inhibits macrophage
activation [1], a role for GDF15 in the regulation of energy balance was
established in 2007, when it was demonstrated that GDF15 sup-
presses food intake [2]. Subsequent pharmacological and genetic
studies conﬁrmed that GDF15 administration lowers body weight,
largely by decreasing appetite [3e7]. Some studies have also sug-
gested that GDF15 can directly increase thermogenesis and improve
insulin sensitivity [8e10]. Recently, the GDNF family receptor a-like
(GFRAL), located in the area postrema of the hindbrain, was identiﬁed
as the receptor that mediates the anorexic effects of GDF15 [4e7].
GDF15 is expressed in most tissues [11] including skeletal muscle
[12], and its abundance generally increases in response to cellular
stress or injury. For example, circulating GDF15 levels are elevated in
patients with cancer or following myocardial injury (reviewed in
[13,14]). In mouse skeletal muscle, GDF15 expression markedly in-
creases in response to mitochondrial stress [8,15], which can lead to
increased plasma GDF15 levels [8]. In humans, circulating GDF15
levels are elevated in patients with muscle atrophy [12] and in patients
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A bout of exercise represents a transient physiological stress [17] that
affects overall energy metabolism by increasing energy expenditure
[17], improving insulin sensitivity [18], and altering food preference
and food intake patterns [19]. During exercise, the contracting skeletal
muscle is challenged by energy (e.g. ADP to ATP ratio), mechanical
(e.g. stretch) and chemical (e.g. reactive oxygen species) stress. In
addition, metformin has been shown to increase serum GDF15 levels
in humans [20]. Both metformin and exercise activate the energy
sensor AMP-activated protein kinase (AMPK) in skeletal muscle
[21,22]. We therefore tested the hypothesis that exercise increases
circulating GDF15 level in humans, by triggering GDF15 release from
skeletal muscle.
2. MATERIAL AND METHODS
2.1. Subjects and diet
Seven men were recruited for the study, which was approved by the
Copenhagen Ethics Committee (Reg. number H-16040740) and per-
formed in accordance with the Declaration of Helsinki. Informed written
consent was received from each participant prior to study inclusion. All
subjects were healthy, moderately physically active, and with no family
history of diabetes. The subjects were 27 1.0 (means  SEM) years
old, with a body weight of 85  3.6 kg, body mass index (BMI) ofy of Science, University of Copenhagen, 2200, Copenhagen, Denmark 2Institute for
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Brief Communication24  0.7 kg/m2 and maximal oxygen uptake (VO2 peak) of
50  1.2 ml/kg/min.
Maximal oxygen uptake was measured by an incremental exercise test
on a Monark Ergomedic 839E bicycle ergometer (Monark, Sweden).
Subjects were studied twice, at least two weeks apart, in a ran-
domized order. One trial was an exercise trial and the other a rest
trial. Before each trial subjects consumed a eucaloric controlled diet
for 3 days to ensure the same conditions before each trial. The daily
energy requirements were individually determined from weighed
dietary registrations and predicted equations from WHO/FAO/UNU. All
food items were weighed and prepared in the metabolic kitchen and
menus were delivered to the subjects and ingested at home. The diet
consisted of 60 energy-percent (E%) carbohydrate, 25E% fat, and
15E% protein.
2.2. Experimental protocol
After three days on the control diet, subjects ingested a light stan-
dardized breakfast (1.6 MJ) at 6 A.M at home. Subjects arrived at the
institute at 8 A.M, and after 10e15 min of supine rest, teﬂon cath-
eters were inserted into the femoral artery and vein under local
anesthesia. After continued supine rest, basal blood samples were
obtained from the femoral artery and vein at 10 A.M (0 min). For the
exercise trial, subjects then initiated a 60 min exercise bout on the
Monark Ergomedic 839E bicycle ergometer at 67  1% of maximal
oxygen uptake (VO2max). Femoral arterial and femoral venous sam-
ples were collected simultaneously during exercise at 20, 40, and
60 min and again after 10 and 120 min of resting supine recovery
without food intake. For the rest trial, subjects remained in the supine
position for 4 h. Arterial blood was collected at 10 A.M. (0 min) and
again after 60 and 180 min of rest matching the time schedule of the
exercise trial.
2.3. Analysis
Blood was sampled in heparinized syringes and transferred to EDTA-
containing tubes and centrifuged at 4 C at 3000g for 5 min.
Plasma was aspirated, frozen, and stored at 80 C until analysis.
GDF15 was measured in plasma using the Quantikine ELISA Human
GDF-15 Immunoassay (ELISA, R&D systems, Inc., Minneapolis, USA,
catalog number: DGD150). Arterial plasma glucose and blood lactate
concentrations and blood hematocrit were measured on an ABL 800
ﬂex (Radiometer Medical, Denmark).
2.4. Statistics
Statistical analyses were performed in SigmaPlot 13.0 (Systat Soft-
ware, Inc., Germany) or in GraphPad Prism 7 (GraphPad Software, Inc.,
USA). For the exercise trial, a two-way ANOVA with repeated mea-
surements (RM) was used. The 20 and 40 min time points were
excluded in this analysis, because four blood samples could not be
analyzed (Table S1). Therefore, for the aev difference data (Figure 1B)
a regular one-way ANOVA was performed to compare differences
among the time points. A two-way ANOVA with RM was used for the
data from the rest trial. When ANOVA analyses revealed signiﬁcant
differences, the Tukey post hoc test was used for multiple compari-
sons. p < 0.05 was considered statistically signiﬁcant.
3. RESULTS
During the exercise trial, plasma GDF15 levels increased from
w215 pg/ml at rest to w295 pg/ml (p < 0.001) at the end of the
exercise bout (Figure 1A). GDF15 further increased to w350 pg/ml
(p < 0.001) at the end of the recovery (Figure 1A). This exercise-188 MOLECULAR METABOLISM 9 (2018) 187e191  2018 The Authors. Published by Elsevier GmbH. Tinduced increase in circulating GDF15 was remarkably consistent,
with GDF15 increasing in every subject. At every time-point, GDF15
concentrations between the femoral artery and femoral vein were
similar (Figure 1AeC). In agreement, the arteriovenous (aev) GDF15
difference was unaffected by exercise and by recovery from exercise
(Figure 1D). Arterial GDF15 plasma levels, measured in the same
subjects during the time- and diet-matched rest study, remained
unchanged (Figure 1E). Absolute changes in arterial GDF15 levels were
2.6-fold (p < 0.05) and 16.7-fold (p < 0.001) higher during the ex-
ercise trial compared to the rest trial at 60 min (exercise stop) and
180 min (recovery), respectively (Figure 1F).
Baseline (0 min) respiratory exchange ratio (RER), oxygen uptake,
plasma glucose, blood lactate, and hematocrit concentrations were
similar in the two trials (Table 1). Throughout the rest trial, these
parameters remained unchanged. During the 60 min-long exercise
bout, oxygen uptake, blood lactate, and hematocrit concentrations
increased signiﬁcantly and returned to baseline levels after 2 h of
recovery (Table 1). Heart rate was 167 5 bpm at the end of exercise.
4. DISCUSSION
Our data demonstrate that circulating GDF15 levels increase with an
acute bout of vigorous submaximal exercise in humans. Furthermore,
we show that this increase does not appear to be mediated by an
exercise-induced release of GDF15 from the exercising muscle,
because venous and arterial concentrations of GDF15 across the
exercised leg were similar. This is the ﬁrst well-controlled study to
measure GDF15 levels during a bout of exercise and in the subsequent
recovery period from exercise. A previous study reported higher GDF15
levels in subjects after a 246 km-long ultramarathon race [23].
However, this is an extreme form of exercise that lasts forw24e36 h;
also, the study lacked crucial time- and diet-matched control groups,
which are imperative for interpretation, especially since GDF15 levels
exhibit considerable diurnal variation in humans [24]. In addition, the
role of skeletal muscle as a potential source of GDF15 has not been
previously assessed in humans.
Our ﬁnding of an exercise-induced increase in GDF15 levels gives rise
to several hypotheses and implications. First, future studies should
clarify whether GDF15 is necessary for some of the exercise-
associated metabolic beneﬁts. Second, given the anorexic nature of
GDF15, it is tempting to speculate that GDF15 is involved in the
transient exercise-induced suppression of appetite in humans [25].
Third, GDF15 is being actively considered as a clinical biomarker, for
example, to predict cardiac complications [14]. Exercise history should
now be accounted for in such applications. Fourth, since skeletal
muscle is not the source of the rise in plasma GDF15 during vigorous
submaximal exercise, the responsible organ(s) as well as the mech-
anisms remain to be identiﬁed in humans. It remains possible that
GDF15 is secreted from muscle to act locally in an autocrine or
paracrine manner, but, notably, Gfral expression was not detected in
peripheral tissues, including skeletal muscle, in the mouse [4].
Our ﬁndings also have limitations. For now, they apply to young,
relatively ﬁt, male subjects. Factors such as sex, age, exercise in-
tensity, the type of exercise, and initial ﬁtness level will have to be
considered in future studies. In addition, a minor part of the increase in
plasma GDF15 during exercise can likely be attributed to an exercise-
induced hemoconcentration, since we detected a rise in hematocrit
concentration of 8e9% during exercise. During recovery, however,
hematocrit levels returned to baseline and therefore, hemoconcen-
tration does not contribute to the marked increase in circulating GDF15
2 h after the exercise bout.his is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
www.molecularmetabolism.com
Figure 1: Vigorous submaximal exercise increases circulating GDF15 in humans. Seven healthy males exercised at 67% of their VO2max for 1 h. Blood, sampled from the
femoral artery and femoral vein, was drawn before (Pre), during (EX) and after (Recovery) exercise at indicated time points. Plasma GDF15 concentrations were determined in these
samples and are shown for each individual subject (A,B) and as means  SEM (C). The matching symbol in A and B represents the same subject. The arteriovenous (aev) GDF15
difference was calculated (D). In the same subjects, plasma GDF15 levels were determined in blood from the femoral artery, collected during a separate rest study (E). Delta (D)
GDF15 levels were calculated for the exercise and rest trial for the indicated time points (F). Data for DeF are also means  SEM. *p < 0.05, ***p < 0.001 compared to Pre (in C)
or as indicated (in F); ###p < 0.001 compared to 60 min.5. CONCLUSION
We have identiﬁed exercise as a disease-unrelated, physiological
stimulus that increases endogenous circulating GDF15 levels in
humans. This exercise effect appears to occur without direct contri-
bution from skeletal muscle.MOLECULAR METABOLISM 9 (2018) 187e191  2018 The Authors. Published by Elsevier GmbH. This is an o
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Table 1 e Respiratory exchange ratio (RER) and oxygen uptake (VO2), as well as plasma glucose, blood lactate and hematocrit (Hct) concentrations determined
in femoral arterial blood sampled at baseline, during 60 min of exercise and subsequent recovery, or during 60 and 180 min of rest.
Baseline Exercise/rest Recovery
0 min 20 min 40 min 60 min 180 min
RER
EX 0.87  0.02 0.98  0.01 0.95  0.01 0.96  0.01yy** 0.85  0.04
REST 0.88  0.03 e e 0.88  0.01 0.89  0.02
VO2 (L,min
L1)
EX 0.3  0.0 2.7  0.1 2.9  0.1 2.9  0.2yyy*** 0.3  0.0
REST 0.3  0.0 e e 0.3  0.0 0.3  0.0
Arterial glucose (mmol∙LL1)
EX 5.4  0.1 5.2  0.2 5.1  0.2 5.7  0.5 5.4  0.1
REST 5.5  0.1 e e 5.4  0.1 5.3  0.1
Arterial lactate (mmol∙LL1)
EX 0.7  0.0 3.9  0.5 3.4  0.4 4.1  0.5yyy*** 0.6  0.0
REST 0.7  0.1 e e 0.7  0.1 0.7  0.1
Hct (%)
EX 45.1  1.0 49.3  0.9 49.5  0.8 48.8  0.8 yyy*** 45.0  1.0
REST 44.6  1.3 e e 45.0  1.3 45.0  1.4
Data are expressed as means  SEM. yyp< 0.01, yyyp< 0.001 different from baseline and recovery values. **p < 0.01, ***p < 0.001 different from REST at the same time point.
20 and 40 min values were excluded from statistical analysis because values at these time points were not obtained in the rest trial.
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